Journal for ImmunoTherapy of Cancer,
Journal Year:
2025,
Volume and Issue:
13(1), P. e010183 - e010183
Published: Jan. 1, 2025
Clear
cell
renal
carcinoma
(ccRCC)
is
the
most
common
histologic
type
of
RCC.
However,
spatial
and
functional
heterogeneity
immunosuppressive
cells
mechanisms
by
which
their
interactions
promote
immunosuppression
in
ccRCC
have
not
been
thoroughly
investigated.
To
further
investigate
cellular
regional
ccRCC,
we
analyzed
single-cell
transcriptome
RNA
sequencing
data
from
four
patients,
were
obtained
samples
multiple
regions,
including
tumor
core,
tumor-normal
interface,
distal
normal
tissue.
On
basis,
findings
investigated
vitro
using
tissue
blood
15
patients
with
validated
broader
on
microarrays.
In
this
study,
revealed
previously
unreported
subsets
both
stromal
immune
cells,
as
well
mapped
location
at
finer
resolution.
addition,
clusters
after
removing
batch
effects
according
to
six
characterized
gene
sets,
epithelial-mesenchymal
transitionhigh
clusters,
metastatic
proximal
tubulehigh
clusters.
Importantly,
identified
a
special
regulatory
T
(Treg)
subpopulation
that
has
molecular
characteristics
terminal
effector
Treg
but
expresses
cytokines,
such
interleukin
(IL)-1β
IL-18.
This
group
stronger
function
was
associated
worse
prognosis
cohorts.
They
colocalized
MRC1
+
FOLR2
tumor-associated
macrophages
(TAMs)
interface
form
positive
feedback
loop,
maintaining
synergistic
procarcinogenic
effect.
traced
origin
IL-1β+
IL-18
can
induce
expression
IL-1β
via
ERK/NF-κB
pathway.
We
demonstrated
novel
cancer-promoting
subset
its
+TAMs,
provides
new
insight
into
potential
therapeutic
targets
for
ccRCC.
Immunity,
Journal Year:
2023,
Volume and Issue:
56(10), P. 2188 - 2205
Published: Oct. 1, 2023
The
cancer-immunity
cycle
provides
a
framework
to
understand
the
series
of
events
that
generate
anti-cancer
immune
responses.
It
emphasizes
iterative
nature
response
where
killing
tumor
cells
by
T
initiates
subsequent
rounds
antigen
presentation
and
cell
stimulation,
maintaining
active
immunity
adapting
it
evolution.
Any
step
can
become
rate-limiting,
rendering
system
unable
control
growth.
Here,
we
update
based
on
remarkable
progress
past
decade.
Understanding
mechanism
checkpoint
inhibition
has
evolved,
as
our
view
dendritic
in
sustaining
anti-tumor
immunity.
We
additionally
account
for
role
microenvironment
facilitating,
not
just
suppressing,
response,
discuss
importance
considering
tumor's
immunological
phenotype,
"immunotype".
While
these
new
insights
add
some
complexity
cycle,
they
also
provide
targets
research
therapeutic
intervention.
Cellular and Molecular Immunology,
Journal Year:
2023,
Volume and Issue:
20(9), P. 983 - 992
Published: July 10, 2023
Abstract
Macrophages
are
critical
regulators
of
tissue
homeostasis
but
also
abundant
in
the
tumor
microenvironment
(TME).
In
both
primary
tumors
and
metastases,
such
tumor-associated
macrophages
(TAMs)
seem
to
support
development.
While
we
know
that
TAMs
dominant
immune
cells
TME,
their
vast
heterogeneity
associated
functions
only
just
being
unraveled.
this
review,
outline
various
known
TAM
populations
found
thus
far
delineate
specialized
roles
with
main
stages
cancer
progression.
We
discuss
how
may
prime
premetastatic
niche
enable
growth
a
metastasis
then
subsequent
metastasis-associated
can
secondary
growth.
Finally,
speculate
on
challenges
remain
be
overcome
research.
Journal of Cancer Research and Clinical Oncology,
Journal Year:
2024,
Volume and Issue:
150(5)
Published: May 7, 2024
Abstract
Background
Tumor
growth
is
closely
linked
to
the
activities
of
various
cells
in
tumor
microenvironment
(TME),
particularly
immune
cells.
During
progression,
circulating
monocytes
and
macrophages
are
recruited,
altering
TME
accelerating
growth.
These
adjust
their
functions
response
signals
from
stromal
Tumor-associated
(TAMs),
similar
M2
macrophages,
key
regulators
TME.
Methods
We
review
origins,
characteristics,
TAMs
within
This
analysis
includes
mechanisms
through
which
facilitate
evasion
promote
metastasis.
Additionally,
we
explore
potential
therapeutic
strategies
that
target
TAMs.
Results
instrumental
mediating
malignant
behaviors.
They
release
cytokines
inhibit
effector
attract
additional
immunosuppressive
primarily
T
cells,
inducing
exhaustion
directly,
influencing
activity
indirectly
cellular
interactions,
or
suppressing
checkpoints.
directly
involved
proliferation,
angiogenesis,
invasion,
Summary
Developing
innovative
tumor-targeted
therapies
immunotherapeutic
currently
a
promising
focus
oncology.
Given
pivotal
role
evasion,
several
approaches
have
been
devised
them.
include
leveraging
epigenetics,
metabolic
reprogramming,
engineering
repolarize
TAMs,
inhibiting
recruitment
activity,
using
as
drug
delivery
vehicles.
Although
some
these
remain
distant
clinical
application,
believe
future
targeting
will
offer
significant
benefits
cancer
patients.
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Sept. 21, 2023
Tumour-associated
macrophages
(TAMs),
as
one
of
the
most
abundant
tumour-infiltrating
immune
cells,
play
a
pivotal
role
in
tumour
antigen
clearance
and
suppression.
M2-like
TAMs
present
heightened
lysosomal
acidity
protease
activity,
limiting
an
effective
cross-presentation.
How
to
selectively
reprogram
reinvigorate
anti-tumour
responses
is
challenging.
Here,
we
report
pH-gated
nanoadjuvant
(PGN)
that
targets
lysosomes
tumours
rather
than
corresponding
organelles
from
healthy
tissues.
Enabled
by
PGN
nanotechnology,
are
specifically
switched
M1-like
phenotype
with
attenuated
cathepsin
activity
for
improved
cross-presentation,
thus
eliciting
adaptive
response
sustained
regression
tumour-bearing
female
mice.
Our
findings
provide
insights
into
how
regulate
function
efficient
cancer
immunotherapy.
